Verona Pharma Share Discussion Threads

[aishah] 24/5/2017 16:13

Equities research analysts at Stifel Nicolaus assumed coverage on shares of Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) in a research note issued on Monday. The firm set a “buy” rating and a $22.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 35.30% from the company’s current price

[127tolmers] 24/5/2017 15:38

Pleased to see 150p barrier broken. Time for a partial EIS exit and let the rest run.

[bewise2] 23/5/2017 15:17

May 23, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference.

An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.

[phowdo] 23/5/2017 10:28

Nasdaq listing and placing all done.
City switches from short to long.
C'est tout simple.

[aishah] 23/5/2017 10:13

Jefferies International initiated with a BUY and 250p target.

[bonzo] 23/5/2017 10:03

What is occurring?

[timbo003] 28/4/2017 07:50

The Nasdaq ticker is VRNA



I'll have a go at changing the header to accommodate an additional real time Nasdaq chart.

[127tolmers] 27/4/2017 10:06

A floor of 132p has now been set by the NASDAQ offer. Hopefully the price quickly moves to a 15% premium post offer and breaks through the 150p barrier and provides a sensible post EIS exit price.

[127tolmers] 18/4/2017 10:27

Timbo, I couldn't go either. I was looking forward to your write up. The 3 year EIS lock-in is over but trading is thin. I guess the 150p (3p in old money)level is going to be a key indicator on sentiment

[aimshares] 18/4/2017 10:05

Timbo,I attended the AGM, it was mentioned that the real money was in PDI &MDI and when Verona were in talks with the Chinese they wanted to see a hand held device. Which Verona are I the process of looking at. Could this have any bearing on things ?

[timbo003] 18/4/2017 09:46

Thanks for spotting that Kwizza

I have fixed the main link to Verona's web site, although I see that there are also a few others (on the Verona web site) which now need updating, I have rectified a couple of them and will look at the rest when I have a bit more time later this week.

[kwizza] 18/4/2017 09:02

timbo, the link to Verona website above is not working, could you have a look

[timbo003] 18/4/2017 08:40

I couldn't make it to the AGM this year (I had it down in my diary for the day before), but I look forward to seeing the AGM slides on the web site.

Today's announcement has me a bit puzzled

With the IND effective, the Company plans to initiate a PK clinical trial in the middle of this year in approximately 12 healthy volunteers to determine the oral bioavailability of RPL554, as well as assess the safety and tolerability of the drug. Top-line data is expected in the fourth quarter of 2017.

Are Verona considering developing an oral dosage form?

[haff1] 07/4/2017 16:34

...not looking so good today?

[ewads] 04/4/2017 07:06

VRP true to their word (not usual for AIM). All the makings for the offer being oversubscribed too.

[vasilis] 31/3/2017 14:57

Tim

The strategy is clearer now in my view after today's announcement. Verona are clearly prepared to 'go it alone' - all the way if necessary and subject to funds. Thus the new collaborations to develop a DPI and MDI rather than any partnering with a big pharma who would no doubt want a deal on their own terms. In addition, bringing in Richard Hennings as the new Commercial Director seems to be linked with this strategy and brings more focus to Verona's own objectives.

If all goes well then with current and future trials, I personally see Verona sticking to their own devices and formulations either as a stand alone company or one that is eventually bought out 'off the peg' so to speak and the offerings would then simply become part of a larger pharma's portfolio of offerings under the Verona 'brand'.

All this of course does depend on the success of RPL554 in various trials. But I assume the new Commercial Director heard enough positives from our CEO to convince him to come on board at this stage. After all, this appointment is very different from the glut of NEDs appointed to the board who are mostly there on behalf of certain major investors.

[timbo003] 31/3/2017 09:23

>>>>Bonzo

I assume they are both private companies (one for DPI and one for MDI) hence no need for them to be named or to announce themselves.

I am a bit disappointed with today's news as the original plan (last year) was to partner mdi and dpi formats with a big pharma and big pharma to pay for the development, so this suggests to me that they still have no takers (at the right price).

If they do end up getting a big pharma partner the work will have to be repeated using the partner's device and formulation.

[bonzo] 31/3/2017 09:06

Pity they do not say who the collaborations on DPI and MDI are with.

[bewise2] 22/3/2017 21:58

Todays RNS another step forward...

[timbo003] 21/3/2017 08:42

Annual report now published


The AGM will be held on April 12th starting at 12:00, I plan to attend

[vasilis] 17/3/2017 08:38

Very interesting Tim and it looks like a change in strategy by AZ in disposing of the US rights of these aclidinium based treatments. As recently as November 2014 AZ made this statement in relation to Duaklir when they obtained EC marketing authorisation -

'The EU approval of Duaklir Genuair marks an important further step in AstraZeneca's inhaled therapy strategy of providing physicians and patients a choice of products uniquely available in both dry powder and pressurised metered dose devices.'

See

Why keep the EC rights yet give up the US rights? And Circassia propose to double their salesforce to promote Tudorza - so clearly they think that it's worth sinking money into promoting Tudorza whereas presumably AZ do not. I suspect that there's more to this than meets the eye as to the deal itself and the enhanced relationship between AZ and Circassia.

Still, the deal once again raises the question as to what price the EU and US rights for a novel treatment such as RPL554 - which to date has not shown the side effects of aclidinium based medicines - might bring at some point in the future.

[timbo003] 17/3/2017 08:02

AN interesting announcement today from Circassia. I'm not sure what's in it for AZ. I guess they may think they have more than enough irons in the fire with their respiratory development portfolio